Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study

Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study

Abstract Introduction Natalizumab is a highly efficacious therapy (HET) for patients with relapsing remitting multiple sclerosis (RRMS). Its prolonged use is limited by the risk of progressive multifocal leukoencephalopathy (PML) in patients positive for anti-JCV antibodies. Aims of this work were t...

Full description

Saved in:
Bibliographic Details
Main Authors: Simona Malucchi, Paola Perini, Francesca Rinaldi, Marta Radaelli, Maria Malentacchi, Antonio Bertolotto, Alessia Di Sapio
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-05-01
Series:Neurology and Therapy
Subjects:
Multiple sclerosis
Patients’ management
Exit strategy
Safety
Online Access:https://doi.org/10.1007/s40120-025-00754-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40120-025-00754-6

Similar Items